Prognostic factors that predict survival after relapse of cervical cancer

CME Journal of Gynecologic Oncology

Volumn 6, Issue 3, 2001, Pages 391-397

  Baalbergen, A ^a   Helmerhorst, T J M ^a   Burger, C W ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Prognostic factors; Recurrent cervical cancer

Indexed keywords

CANCER LOCALIZATION; CANCER RECURRENCE; CANCER SIZE; CANCER SURVIVAL; FEMALE; HISTOPATHOLOGY; HUMAN; LYMPH NODE METASTASIS; PREDICTION; PROGNOSIS; RECURRENT CANCER; REVIEW; UTERINE CERVIX CANCER;

EID: 0035679635     PISSN: 12199087     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (55)

1. Epidemiology of cervical cancer
2. Squamous cell carcinoma antigen and carcinoembryonic antigen levels as prognostic factors for the response of cervical carcinoma to chemotherapy
3. Weekly cisplatin induction chemotherapy in the treatment of recurrent cervical carcinoma
4. Patterns of recurrence of carcinoma following radical hysterectomy
5. Radiotherapy for the treatment of locally recurrent cervical cancer
6. Recurrent cervical carcinoma after radical hysterectomy
7. Optimal management of locally advanced cervical carcinoma
8. Prognostic factors for local control in recurrent cervical carcinoma treated with IORT: Report of the French IORT Group
9. Clinical patterns of tumor recurrence after radical hysterectomy in stage IB cervical carcinoma
10. Optimal therapy for pelvic recurrence after radical hysterectomy for early-stage cervical cancer
11. Surgery for the treatment of locally recurrent disease
12. Factors affecting the response of recurrent squamous cell carcinoma of the cervix to cisplatin
13. The prognostic factors for patients with early cervical cancer treated by radical hysterectomy and postoperative radiotherapy
14. Recurrence and survival analysis of 1115 cervical cancer patients treated with radical hysterectomy
15. Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix
16. Treatment outcome of recurrent cervical cancer
17. Long-term results of concurrent radiation and chemotherapy for carcinoma of the cervix recurrent after surgery
18. Prognostic factors and relapse patterns in early-stage cervical carcinoma after brachytherapy and radical hysterectomy
19. Relapse patterns in FIGO stage IB carcinoma of the cervix
20. Radiation therapy of pelvic recurrence after radical hysterectomy for cervical carcinoma
21. Post-surgical recurrent carcinoma of the cervix: Reassessment and results of radiation therapy options
22. Cervical carcinoma recurrences and their treatment at the University of Freiburg's Women's Clinic from 1976 to 1985
23. Concurrent carboplatin/5-fluorouracil and radiotherapy for recurrent cervical carcinoma
24. Recurrent cervical carcinoma after primary radical surgery
25. Five-year experience with combined operative and radiotherapeutic treatment of recurrent gynecologic tumors infiltrating the pelvic wall
26. Intraoperative radiation therapy in gynecologic cancer: The Mayo Clinic experience
27. Late recurrent carcinoma of the cervix: A report of an unusual case and course
28. Chemotherapy of advanced and recurrent cervical carcinoma
29. Chemotherapy for cervical carcinoma: Factors determining response and implications for clinical trial design
30. Randomized trial of cisplatin versus cisplatin plus mitolactol versus cisplatin plus ifosfamide in advanced squamous carcinoma of the cervix: A Gynecologic Oncology Group study
31. The role of chemotherapy in squamous cell carcinoma of the uterine cervix: A review
32. Phase II trial of vinorelbine in patients with advanced and/or recurrent cervical carcinoma: An EORTC Gynaecological Cancer Cooperative Group Study
33. Chemotherapy for stage IVB or recurrent cancer of the uterine cervix
34. First-line chemotherapy with paclitaxel and platinum for advanced and recurrent cancer of the cervix - A phase II study
35. Chemotherapy with paclitaxel, ifosfamide, and cisplatin for the treatment of squamous cell cervical cancer: The experience of Monza
36. A phase II trial of mitomycin, ifosfamide and cisplatin in recurrent carcinoma of the cervix
37. A short and intensive single-agent cisplatin regimen for recurrent carcinoma of the uterine cervix
38. Cisplatin/5-fluorouracil treatment of recurrent cervical carcinoma: A phase II study with long-term follow-up
39. Carboplatin/5-fluorouracil treatment of recurrent cervical carcinoma: A phase II study with long-term follow-up
40. A phase I/II study of combined weekly systemic cisplatin and locoregional hyperthermia in patients with previously irradiated recurrent carcinoma of the uterine cervix
41. Phase II trial of weekly locoregional hyperthermia and cisplatin in patients with a previously irradiated recurrent carcinoma of the uterine cervix
42. Factors predicting response to chemotherapy and survival in patients with metastatic or recurrent squamous cell cervical carcinoma: A multivariate analysis
43. Phase II study of vincristine, bleomycin, mitomycin C and cisplatin (VBMP) in disseminated squamous cell carcinoma of the uterine cervix
44. Surgical pathologic factors that predict recurrence in stage IB and IIA cervical carcinoma patients with negative pelvic lymph nodes
45. Surgical treatment of carcinoma of the cervix, recurrent after irradiation or combination of irradiation and surgery
46. Outcome of recurrent cervical carcinoma following definitive irradiation
47. Clinicopathological study of recurrent uterine cervical squamous-cell carcinoma
48. Invasive squamous cell carcinoma of the cervix in women less than 35-years old: Recurrent versus nonrecurrent disease
49. Prognostic significance of the bcl-2 apoptotic family of proteins in primary and recurrent cervical cancer
50. The possible role of p53 and bcl-2 expression in cervical carcinomas and their premalignant lesions
51. Oncogene expression and microvessel count in recurrent and nonrecurrent stage IB squamous cell carcinoma of the cervix
52. Predicting response to neoadjuvant chemotherapy in patients with cervical carcinoma: Can we do without any longer?
53. Posttherapy surveillance of women with cervical cancer: An outcomes analysis
54. The place for surgery in central recurrences of invasive cancer of cervix uteri
55. Tumor recurrence and survival in stage IB cancer of the cervix